8人のウォール街のアナリストによると、ICU Medical Incの収益見積もりは$553.55Mから$507.25Mの範囲です。
ICU Medical Incの収益品質スコアはどれくらいですか?
ICU Medical Incの収益品質スコアはB+/56.10606です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
ICU Medical Incはいつ収益を報告しますか?
ICU Medical Incの次の収益報告は2026-05-20に予定されています
ICU Medical Incの予想収益はいくらですか?
ウォール街のアナリストによると、ICU Medical Incの予想収益は$541.24Mです。
ICU Medical Incは収益予想を上回りましたか?
ICU Medical Incの最近の収益は$535.94Mで、予想を打ち勝たない。
主要データ
前終値
$129.4
始値
$130.87
当日レンジ
$126.62 - $131.85
52週レンジ
$107 - $160.29
取引高
274.6K
平均取引高
271.9K
配当利回り
--
1株当たり利益(TTM)
0.02
時価総額
$3.2B
ICUIとは何ですか?
ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 13,000 full-time employees. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.